{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:37Z","timestamp":1791874717336,"version":"4.3.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The actin binding protein filamin A (FLNA) is required for somatostatin receptor 2 (SSTR2) and dopamine receptor 2 (DRD2) expression and signaling in GH- and PRL-secreting PitNETs, respectively, playing a role in tumor responsiveness to somatostatin receptors ligands and dopaminergic drugs. FLNA functions are regulated by several mechanisms, including phosphorylation. It has been shown that in GH-secreting PitNETs FLNA phosphorylation on Ser2152 (P-FLNA) switches FLNA function from a scaffold that allows SSTR2 signal transduction, to a signal termination protein that hampers SSTR2 antitumoral effects. Aims of the present study were to evaluate in PRL- and ACTH-secreting PitNETs cell lines MMQ and AtT-20 the effects of cAMP pathway activation and DRD2 agonist on P-FLNA and the impact of P-FLNA on DRD2 signal transduction. We found that forskolin increased (+2.2 \u00b1 0.8-fold, p &amp;lt; 0.01 in MMQ; +1.9 \u00b1 0.58-fold, p &amp;lt; 0.05 in AtT-20), and DRD2 agonist BIM53097 reduced (-49.4 \u00b1 25%, p &amp;lt; 0.001 in MMQ; -45.8 \u00b1 28%, p &amp;lt; 0.05 in AtT-20), P-FLNA on Ser2152. The overexpression of a phosphomimetic (S2152D) FLNA mutant in both cell lines prevented DRD2 antiproliferative effects, that were comparable in cells transfected with empty vector, wild-type FLNA as well as phosphodeficient FLNA mutant (S2152A) (-20.6 \u00b1 5% cell proliferation, p &amp;lt; 0.001 in MMQ; -36.6 \u00b1 12%, p &amp;lt; 0.01 in AtT-20). Accordingly, S2152D FLNA expression abolished the expected ability of BIM53097 to increase or decrease, in MMQ and in AtT20 respectively, ERK phosphorylation, an effect that was maintained in S2152A FLNA expressing cells (+1.8 \u00b1 0.65-fold, p &amp;lt; 0.05 in MMQ; -55 \u00b1 13%, p &amp;lt; 0.01 in AtT-20). In addition, the inhibitory effects of DRD2 on hormone secretion (-34.3 \u00b1 6% PRL, p &amp;lt; 0.05 in MMQ; -42.8 \u00b1 22% ACTH, p &amp;lt; 0.05 in AtT-20, in cells expressing S2152A FLNA) were completely lost in S2152D FLNA transfected cells. In conclusion, our data demonstrated that cAMP pathway and DRD2 agonist regulated FLNA activity by increasing or decreasing, respectively, its phosphorylation. Moreover, we found that P-FLNA prevented DRD2 signaling in PRL- and ACTH-secreting tumoral pituitary cell lines, suggesting that this FLNA modification might represent a new regulatory mechanism shared by different GPCRs. In PitNETs expressing DRD2, modulation of P-FLNA might suggest new pharmacological strategies to overcome drug resistance, and P-FLNA might represent a new biomarker for tumor responsiveness to dopaminergic agents.<\/jats:p>","DOI":"10.3389\/fendo.2020.611752","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T12:05:53Z","timestamp":1613649953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP\/PKA-Induced Filamin A Phosphorylation"],"prefix":"10.3389","volume":"11","author":[{"given":"Federica","family":"Mangili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Treppiedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genesio","family":"Di Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Peverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J Mol Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Endocrine Society. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00469","article-title":"Dopamine agonists for pituitary adenomas","volume":"9","author":"Cooper","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0936-7","article-title":"Effect of cabergoline monotherapy in Cushing\u2019s disease: an individual participant data meta-analysis","volume":"41","author":"Palui","year":"2018","journal-title":"Endocrinol Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-1014","article-title":"Cabergoline in severe ectopic or occult Cushing\u2019s syndrome","volume":"181","author":"Ilie","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","article-title":"Somatostatin and dopamine receptors as targets for medical treatment of Cushing\u2019s syndrome","volume":"10","author":"de Bruin","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1385\/endo:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","author":"Stefaneanu","year":"2001","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2005.01.007","article-title":"Pituitary surgery and postoperative management in Cushing\u2019s disease Metab","volume":"34","author":"Utz","year":"2005","journal-title":"Clin North Am"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0397-5","article-title":"Medical management of Cushing\u2019s disease: what is the future","volume":"15","author":"Fleseriu","year":"2012","journal-title":"Pituitary"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.12.4747","article-title":"Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","author":"Caccavelli","year":"1994","journal-title":"Neuroendocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000156116","article-title":"Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists","volume":"89","author":"Passos","year":"2009","journal-title":"Neuroendocrinology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2826.1996.04902.x","article-title":"Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas","volume":"8","author":"Caccavelli","year":"1996","journal-title":"J\u00a0Neuroendocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2902","article-title":"Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs","volume":"97","author":"Peverelli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2008.1","article-title":"Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas","volume":"8","author":"Filopanti","year":"2008","journal-title":"Pharmacogenom J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11102-016-0776-4","article-title":"Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment","volume":"20","author":"Bueno","year":"2017","journal-title":"Pituitary"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1820","article-title":"Activation of the dopamine receptor type-2 (drd2) promoter by 9-cis retinoic acid in a cellular model of cushing\u2019s disease mediates the inhibition of cell proliferation and acth secretion without a complete corticotroph-to-melanotroph transdifferentiation","volume":"155","author":"Occhi","year":"2014","journal-title":"Endocrinology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2015.00187","article-title":"Dopamine and somatostatin analogues resistance of pituitary tumors: focus on cytoskeleton involvement","volume":"6","author":"Peverelli","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/ERC-18-0442","article-title":"Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors","volume":"26","author":"Mantovani","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1384520","article-title":"Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP\/PKA dependent phosphorylation","volume":"46","author":"Peverelli","year":"2014","journal-title":"Horm Metab Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.08.002","article-title":"cAMP\/PKA-induced filamin A (FLNA) phosphorylation inhibits SSTR2 signal transduction in GH-secreting pituitary tumor cells","volume":"435","author":"Peverelli","year":"2018","journal-title":"Cancer Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4161\/cam.5.2.14401","article-title":"The Filamins: Organizers of cell structure and function","volume":"5","author":"Nakamura","year":"2011","journal-title":"Cell Adh Migr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.2000.1762","article-title":"Determination of a cAMP-dependent protein kinase phosphorylation site in the C-terminal region of human endothelial actin-binding protein","volume":"377","author":"Jay","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.24.7.3025-3035.2004","article-title":"Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site","volume":"24","author":"Woo","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1063-12.2012","article-title":"Brefeldin A-inhibited guanine exchange factor 2 regulates filamin A phosphorylation and neuronal migration","volume":"32","author":"Zhang","year":"2012","journal-title":"J Neurosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2009.08.059","article-title":"Phosphorylation facilitates the integrin binding of filamin under force","volume":"97","author":"Chen","year":"2009","journal-title":"Biophys J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)71675-X","article-title":"In situ phosphorylation of platelet actin-binding protein by cAMP-dependent protein kinase stabilizes it against proteolysis by calpain","volume":"264","author":"Chen","year":"1989","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.633446","article-title":"A mechanism of global shape-dependent recognition and phosphorylation of filamin by protein kinase A","volume":"290","author":"Ithychanda","year":"2015","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.011538198","article-title":"Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A","volume":"98","author":"Lin","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30613","article-title":"Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor\/stem-like cells isolated from non functioning pituitary tumors","volume":"140","author":"Peverelli","year":"2017","journal-title":"Int J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41598-018-37692-3","article-title":"Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles","volume":"9","author":"Coelho","year":"2019","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00947-x","article-title":"Filamin A and DRD2 expression in corticotrophinomas","volume":"22","author":"Sickler","year":"2019","journal-title":"Pituitary"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.222319599","article-title":"Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs","volume":"99","author":"Iaccarino","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/me.2013-1008","article-title":"Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia","volume":"27","author":"Radl","year":"2013","journal-title":"Mol Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2018.12.022","article-title":"Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1\/2 activity","volume":"483","author":"Treppiedi","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5744","article-title":"Suppression of mTOR pathway and induc-tion of autophagy-dependent cell death by cabergoline","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000509219","article-title":"\u03b2-Arrestin 2 is required for dopamine receptor type 2 inhibitory effects on AKT phosphorylation and cell proliferation in pituitary tumors","author":"Mangili","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549020-00009","article-title":"Cabergoline a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation","volume":"49","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000317716","article-title":"Medical treatment in Cushing\u2019s syndrome: dopamine agonists and cabergoline","author":"Petrossians","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)80387-0","article-title":"Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine","volume":"339","author":"Yin","year":"1994","journal-title":"FEBS Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0955-0674(99)00078-2","article-title":"Signal transduction: hanging on a scaffold","volume":"12","author":"Burack","year":"2000","journal-title":"Curr Opin Cell Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/gtc.12366","article-title":"Mammalian target of rapamycin (mTOR) complex 2 regulates filamin A-dependent focal adhesion dynamics and cell migration","volume":"21","author":"Sato","year":"2016","journal-title":"Gene Cells"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.611752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T12:05:56Z","timestamp":1613649956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.611752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":47,"alternative-id":["10.3389\/fendo.2020.611752"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.611752","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"article-number":"611752"}}